Onxeo Announces a Combined General Meeting on August 17, 2022
Onxeo has announced a Combined General Meeting on August 17, 2022, at 2:00 pm CEST in Paris. Shareholders will vote on the proposal to delist from Nasdaq First North to consolidate listing on Euronext Growth, potentially enhancing liquidity. Meeting details and documents will be made available on the company’s website as required.
Onxeo specializes in innovative oncology drugs targeting DNA Damage Response (DDR) and is developing compounds like AsiDNA and the OX400 series, which focus on overcoming tumor resistance and enhancing immune response.
- Proposal to delist from Nasdaq First North to centralize listing on Euronext Growth, potentially increasing liquidity
- Ongoing development of innovative drugs targeting DNA Damage Response with potential commercial value
- None.
The meeting notice will be published in the BALO (Bulletin of Mandatory Legal Notices) on
Shareholders are notably invited to vote on the delisting of the Company from Nasdaq First North market in
All documents relating to this general meeting will be uploaded on the Company's website in the General Meetings section within the legal deadlines (15 days prior to the meeting), and shareholders will be notified by a company announcement.
For any question, please contact the Investor Relations team by e-mail at the dedicated address: ag2022@onxeo.com.
About
platON is Onxeo’s proprietary chemistry platform of oligonucleotides acting as decoy agonists, which generates new innovative compounds and broaden the Company’s product pipeline.
AsiDNA, the first compound from platON, is a highly differentiated, clinical-stage first-in-class candidate in the field of DNA damage response (DDR) applied to oncology. Its decoy and agonist mechanism acting upstream of multiple DDR pathways results in distinctive antitumor properties, including the ability to prevent or abrogate tumor resistance to targeted therapies such as PARP inhibitors and strong synergy with tumor DNA-damaging agents such as radio-chemotherapy. AsiDNA is currently being studied in
OX400 is a series of new drug candidates from platON, designed to be a next-generation PARP inhibitor acting on both the DNA Damage Response and the activation of immune response, without inducing resistance. The lead OX400 candidate is currently being optimized and is undergoing preclinical proof-of-concept studies, alone and in combination with immunotherapies.
For further information, please visit www.onxeo.com.
Forward looking statements
This communication expressly or implicitly contains certain forward-looking statements concerning
View source version on businesswire.com: https://www.businesswire.com/news/home/20220712006024/en/
Investor Relations
investors@onxeo.com
+33 1 45 58 76 00
Media Relations
Arthur Rouillé
NewCap
onxeo@newcap.eu
+33 1 44 71 94 98
Investor Relations / Strategic Communication
Dušan Orešanský /
NewCap
onxeo@newcap.eu
+33 1 44 71 94 92
Certified Adviser for Nasdaq First North
Kapital Partner
www.kapitalpartner.dk
info@kapitalpartner.dk
+45 89 88 78 46
Source:
FAQ
What is the purpose of Onxeo's Combined General Meeting on August 17, 2022?
What drugs are Onxeo currently developing?
When will the notice for the Combined General Meeting be published?